By the end of the day's trade on 28 January 2022, ASX 200 settled in the green zone after a continuous selling of 2 weeks. The benchmark index gained 2.191% and settled at 6988.1. The index settled higher on 28 January 2022 because of a good gain in almost all the indices on ASX. Indices like consumer discretionary, consumer staples, healthcare, and telecommunication services sectors were amongst the strong performers for the day, with a significant gain of near 3% in their respective index values. The consumer discretionary sector was the top gainer, with a rise of 3.27% in the index value.
In the past five days, the index lost 2.62%. However, it has gained 5.09% over the last 52-weeks.
Top performing Sectors for the day:
Consumer discretionary (Up: 3.268%)
Consumer staples (Up: 3.257%)
Telecommunication services (Up: 2.894%)
Healthcare (Up: 2.72%)
Energy sector performs least today with the gain of 0.82% at the closing.
Top Gainers and Losers:
On 27 January 2022, Imugene Limited (ASX: IMU) and Polynovo Limited (ASX: PNV) were amongst the top gainers on ASX 200. At the same time, Ramelius Resources Limited (ASX: RMS) and Newcrest Mining Limited (ASX: NCM) were the top two losers on ASX.
IMU shares surged as the company announced clinical trial supply agreement with Roche to evaluate PD1-vaxx for treatment of lung cancer. On the other hand, RMS shares declined due to below estimated quarterly numbers.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Maven Capital Pty Ltd (AFSL No. 418504). The information contained in this article is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Suite 1A, Level 2, 802-808 Pacific Highway, Gordon NSW 2072, Australia | 1800 005 780 | info@kapitales.com.au.au
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Market Close Commentary: 28 January 2022
By the end of the day's trade on 28 January 2022, ASX 200 settled in the green zone after a continuous selling of 2 weeks. The benchmark index gained 2.191% and settled at 6988.1. The index settled higher on 28 January 2022 because of a good gain in almost all the indices on ASX. Indices like consumer discretionary, consumer staples, healthcare, and telecommunication services sectors were amongst the strong performers for the day, with a significant gain of near 3% in their respective index values. The consumer discretionary sector was the top gainer, with a rise of 3.27% in the index value.
Copyright © 2022 Kapitales Research
In the past five days, the index lost 2.62%. However, it has gained 5.09% over the last 52-weeks.
Top performing Sectors for the day:
Top Gainers and Losers:
On 27 January 2022, Imugene Limited (ASX: IMU) and Polynovo Limited (ASX: PNV) were amongst the top gainers on ASX 200. At the same time, Ramelius Resources Limited (ASX: RMS) and Newcrest Mining Limited (ASX: NCM) were the top two losers on ASX.
IMU shares surged as the company announced clinical trial supply agreement with Roche to evaluate PD1-vaxx for treatment of lung cancer. On the other hand, RMS shares declined due to below estimated quarterly numbers.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Maven Capital Pty Ltd (AFSL No. 418504). The information contained in this article is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Suite 1A, Level 2, 802-808 Pacific Highway, Gordon NSW 2072, Australia | 1800 005 780 | info@kapitales.com.au.au